- CIIX CEO said company will employ social media as it markets new CBD products starting March 2020
- CIIX subsidiary CBD Biotech Co. focused on driving growth, building online sales to younger demographics in China
- Goals of CIIX strategy include profitability, expansion of market, maximized impact
ChineseInvestors.com Inc. (OTCQB: CIIX) CEO Warren Wang said the company will adopt social media multiplatform techniques to market new CBD products beginning in March 2020. The move is designed to boost online sales to a younger demographic in China through its subsidiary CBD Biotech, explained Wang during a MoneyTV interview with host Donald Baillargeon. In the interview, Wang also outlined the company’s path to profitability in fiscal 2020 and 2021.
“CBD Biotech’s goal in 2020 is to make a profit,” Wang stated in the interview. “That is the key of the stock market. That’s the key for our stock price. That’s the key for our shareholders. CIIX plans to launch a breakthrough CBD product in March. It will debut through its B2B partners through social media, such as TikTok, and target in China a lot of young people.”
One important aspect of the company’s strategy to increase profit is to sell its new CBD product through e-commerce using different social media platforms in 2020. Wang observed that multi-platform social media would play a key role in the company’s marketing to a younger consumer audience of its CBD line. He specifically mentioned using platforms such as TikTok in the campaign, which launched in 2017 and accrued 500 million users in its first two years. Recently hailed as a “must for every small business,” social media marketing gives companies more direct access to their customers, meeting them where they are in a cost-effective way. Social media marketing has also been linked with increased brand recognition (http://ibn.fm/YOANZ), allowing companies to “target and retarget ideal consumers.” CIIX hopes to engage audiences of all ages through social media as it increases traction for its new CBD offerings.
In addition to its anticipated CBD product, CBD Biotech currently markets a line of hemp-infused cosmetics products in China. Wang estimates that cosmetics could deliver profit margins of 10-20 times for the company (http://ibn.fm/G89BP). “That’s quite a big profit,” he noted.
Referencing the high gross margins of CBD cosmetics, Wang said the company is working to bring more of that profitability down to the bottom line through lower costs and a restructuring. Wang explained that CIIX intends to expand its market as it maximizes sales through a split configuration of its B2B and B2C divisions.
The B2C division would focus on marketing and selling to consumers while the B2B division would be responsible for maximizing revenue to wholesalers and through multilevel social media outlets, he explained. The combined aim of the two divisions is to raise sales, cut costs and achieve profitability, he said.
Wang sees subsidiary CBD Biotech company reaching profitability by Q4 2020 fiscal year and continuing into 2021. “I am very positive about CBD in 2020, very excited,” he concluded.
CIIX is a diverse company driven not only by sales of cosmetics, hemp wine and CBD but also educational services. CIIX offers its audience of Chinese-speaking investors real-time market commentary, analysis and educational-related services in Chinese character language sets.
For more information, visit the company’s website at www.ChineseInvestors.com
NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.